Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Increased to $36.00 by Analysts at JPMorgan Chase & Co.

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target raised by JPMorgan Chase & Co. from $32.00 to $36.00 in a research report report published on Monday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other research firms have also recently weighed in on DAWN. Piper Sandler reaffirmed an overweight rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Oppenheimer reaffirmed a market perform rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a research report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $39.83.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $15.38 on Monday. The company’s 50 day simple moving average is $15.22 and its 200-day simple moving average is $13.75. Day One Biopharmaceuticals has a 52-week low of $9.67 and a 52-week high of $17.85. The firm has a market capitalization of $1.34 billion, a P/E ratio of -6.46 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Sell-side analysts predict that Day One Biopharmaceuticals will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares in the company, valued at $18,981,095.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the transaction, the insider now owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 20,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total transaction of $322,200.00. Following the completion of the sale, the insider now directly owns 1,224,662 shares of the company’s stock, valued at approximately $19,729,304.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,781 shares of company stock worth $883,160. Insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock worth $56,807,000 after purchasing an additional 346,090 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Day One Biopharmaceuticals by 38.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock valued at $5,486,000 after purchasing an additional 125,050 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Day One Biopharmaceuticals by 22.4% in the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after buying an additional 40,387 shares during the last quarter. TimesSquare Capital Management LLC boosted its holdings in shares of Day One Biopharmaceuticals by 41.8% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock worth $14,020,000 after buying an additional 336,910 shares during the period. Finally, Deutsche Bank AG grew its stake in Day One Biopharmaceuticals by 5.5% in the 3rd quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock valued at $2,173,000 after buying an additional 9,219 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.